Zoetis Inc Cash Flow Conversion Efficiency
Zoetis Inc cash flow conversion efficiency. Based on the latest financial reports, Zoetis Inc (ZTS) has a cash flow conversion efficiency ratio of 0.174x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($938.00 Million) by net assets ($5.40 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ZTS stock market capitalisation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Zoetis Inc (2010–2024)
Cash flow conversion efficiency of Zoetis Inc from 2010 to 2024. This chart illustrates how Zoetis Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Zoetis Inc (ZTS) share price today for real-time trading data and today's change.
Zoetis Inc Cash Flow Conversion Ratio Explained
Zoetis Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Zoetis Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zoetis Inc ranked by their cash flow conversion efficiency. Review Zoetis Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Telefonaktiebolaget LM Ericsson B ADR
NASDAQ:ERIC
|
0.075x |
|
Fairfax Financial Holdings Ltd
TO:FFH
|
0.038x |
|
Waters Corporation
NYSE:WAT
|
0.000x |
|
Swiss Re AG
SW:SREN
|
0.062x |
|
Trip.com Group Ltd ADR
NASDAQ:TCOM
|
0.087x |
|
Teva Pharmaceutical Industries Limited
F:TEV
|
-0.005x |
|
SSE PLC ADR LS-50 1
F:SCTA
|
N/A |
|
Honda Motor Co. Ltd
F:HDMA
|
0.023x |
Annual Cash Flow Conversion Efficiency for Zoetis Inc (2010–2024)
The table below shows the annual cash flow conversion efficiency of Zoetis Inc from 2010 to 2024. Also see ZTS asset base for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $4.77 Billion | $2.95 Billion | 0.619x | +31.31% |
| 2023-12-31 | $4.99 Billion | $2.35 Billion | 0.471x | +8.57% |
| 2022-12-31 | $4.40 Billion | $1.91 Billion | 0.434x | -10.83% |
| 2021-12-31 | $4.54 Billion | $2.21 Billion | 0.487x | -13.57% |
| 2020-12-31 | $3.77 Billion | $2.13 Billion | 0.563x | -14.99% |
| 2019-12-31 | $2.71 Billion | $1.79 Billion | 0.663x | -19.09% |
| 2018-12-31 | $2.19 Billion | $1.79 Billion | 0.819x | +8.70% |
| 2017-12-31 | $1.79 Billion | $1.35 Billion | 0.754x | +58.44% |
| 2016-12-31 | $1.50 Billion | $713.00 Million | 0.476x | -21.85% |
| 2015-12-31 | $1.09 Billion | $664.00 Million | 0.609x | +29.99% |
| 2014-12-31 | $1.34 Billion | $626.00 Million | 0.468x | -33.86% |
| 2013-12-31 | $962.00 Million | $681.00 Million | 0.708x | +530.09% |
| 2012-12-31 | $4.04 Billion | $454.00 Million | 0.112x | -15.55% |
| 2011-12-31 | $3.74 Billion | $497.00 Million | 0.133x | +75.14% |
| 2010-12-31 | $3.34 Billion | $254.00 Million | 0.076x | -- |
About Zoetis Inc
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and… Read more